Celebrex FAP Study Will Explore Delay Of Surgery In Pediatric Patients
Executive Summary
Searle will examine the efficacy of Celebrex for delay of surgery in non-symptomatic adolescent patients with familial adenomatous polyposis, the company told FDA's Oncologic Drugs Advisory Committee Dec. 14.
You may also be interested in...
Pfizer Celebrex Polyp Trials Get Added Weight With Vioxx Withdrawal
Two trials for the COX-2 inhibitor Celebrex in prevention of adenomatous polyps take on added significance following Merck's withdrawal of Vioxx
Pfizer Celebrex Polyp Trials Get Added Weight With Vioxx Withdrawal
Two trials for the COX-2 inhibitor Celebrex in prevention of adenomatous polyps take on added significance following Merck's withdrawal of Vioxx
Celebrex Labeling For Polyps Should Emphasize Adjunctive Role, Cmte. Says
Searle's Celebrex labeling for reduction of adenomatous colorectal polyps should emphasize monitoring and urge surgery when needed, FDA's Oncologic Drugs Advisory Committee suggested at its Dec. 14 meeting.